Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29889649 | 0.70 | BPTF (0.42) | L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL2137892 | 0.69 | L3MBTL1 (0.59) | L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL3753324 | 0.68 | L3MBTL1 (0.64) | L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL29889371 | 0.68 | BPTF (0.43) | L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL11742016 | 0.67 | L3MBTL1 (0.52) | L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL11922747 | 0.67 | HSD17B10 (0.74) | L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL19574088 | 0.67 | ATM (0.72) | L3MBTL1TSHRSMN1; SMN2MEN1TP53 | |
| SCHEMBL18051852 | 0.67 | SMN1; SMN2 (0.39) | SMN1; SMN2MEN1TP53KMT2AHPGD | |
| SCHEMBL15723527 | 0.67 | SMN1; SMN2 (0.42) | SMN1; SMN2MEN1TP53KMT2AGAA | |
| SCHEMBL2262931 | 0.66 | L3MBTL1 (0.61) | L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3141252-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | Vertex Pharmaceuticals Inc. (US) | 2017-03-15 | — | — | EP | disclosed |
| US-9518056-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-12-13 | — | — | US | disclosed |
| US-20120171245-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120171245-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, IRF3, ACE2 | L3MBTL1 4645/4885TSHR 2310/4885ALOX15 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.